Today, Emm, the British-based innovator in biowearable technology, announces it has raised €7.7 million ($9 million) in an oversubscribed Seed funding round, to bring the world’s first smart menstrual cup and connected app to market.
The round was led by Lunar Ventures, with additional participation from the Labcorp Venture Fund, Tiny VC, BlueLion Global, Alumni Ventures, and angels including Amar Shah (co-founder of Wayve), Vivek Garipalli (founder of Clover Health and Wormhole Capital), and Harpreet Rai (former CEO, Oura). Emm has also received non-dilutive funding, including grants that support innovation in women’s health technology.
Jenny Button, founder and CEO of Emm, states: “Menstruation is known as the fifth vital sign, but has historically been overviewed by the wearable sector, leaving millions without the data they necessary to understand and advocate for their own bodies. We envision a future where menstrual health is measured and understood as comprehensively as cardiovascular or metabolic health, giving people access to objective, actionable insights to better manage their health and wellbeing.”
Recent 2025 funding activity on EU-Startups displays several adjacent developments in Europe’s FemTech and health-wearable space.
Hormona in London secured €7.8 million in a Seed round to advance its hormone-tracking platform, signalling sustained UK-based momentum in women’s health technology. In the Netherlands, YON E Health raised €250k at pre-Seed to develop a smart device measuring vaginal pH and basal body temperature. Meanwhile, French MedTech company RDS closed a €14 million Series A round to industrialise its connected patch for remote patient monitoring.
Toobtainher, these rounds represent approximately €22 million flowing into Europe’s broader connected-health and women’s-health technology ecosystem in 2025.
Within this landscape, Emm’s Seed round positions the Bristol startup among the larger early-stage raises in the category. Its focus on a menstrual-health biowearable distinguishes it from the hormone-tracking, vaginal-health, and general remote-monitoring devices that have attracted funding this year.
Grace E. Colón, PhD, Board Chair, adds: “Emm’s technology has the potential to serve as both a biological sample and data insights platform, unlocking new knowledge and opportunities for researchers and BioTech focutilized on women’s health and beyond. I am thrilled to partner with Jenny and her team to provide tools that are desperately necessaryed and catalyse what we anticipate will be major advances for patients.”
Founded in 2020, Emm is developing the world’s first smart menstrual solution. Combining ultra-thin advanced sensor technology with medical-grade silicone, Emm delivers insights into the menstrual cycle and broader health – providing utilizers with a data-driven understanding of their body.
Developed over five years with thousands of design iterations and extfinished utilizer testing, the non-intrusive cup integrates medical-grade silicone with ultra-thin advanced sensor technology.
The accompanying connected app automatically collates baseline data over time, allowing utilizers to identify and track patterns, understand their own biology and have more effective conversations with healthcare professionals about their symptoms, in just three cycles.
Launching to consumers in the UK in early 2026, Emm will equip utilizers to track key metrics for personalised, actionable insights into their menstrual health. The waitlist for new subscribers is now open via the Emm website with other markets soon to follow.
Mick Halsband, Partner at Lunar Ventures, shares: “We’re proud to back Jenny and the Emm team as they build the foundational technology to transform women’s health and drive measurable impact in chronic diseases. At Lunar, we invest in founders tackling complex engineering challenges across data, materials, and biological systems, and Emm exemplifies this with its world-class hardware and high-fidelity data. Their world-first platform has the potential to redefine standards of care and data quality in menstrual health and beyond.”
Leave a Reply